Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-Label, Parallel-Group, Pre-surgical Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2-negative Primary Breast Cancer (SERENA-3)

NCT04588298 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04588298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04588298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-Label, Parallel-Group, Pre-surgical Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2-negative Primary Breast Cancer (SERENA-3)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2020
Completion date
June 19, 2023
Enrollment
135 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer